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Skin conditions may have a strong impact on patients’ 
sexual life, and thus influence personal relationships. 
Sexual issues are difficult to discuss directly in clini-
cal practice, and a mediated instrument may be useful 
to capture such information. In this study item 9 of 
the Dermatology Life Quality Index was used to collect 
information on sexual impact of several skin condi-
tions in 13 European countries. Among 3,485 patients, 
23.1% reported sexual problems. The impairment was 
particularly high in patients with hidradenitis suppura-
tiva, prurigo, blistering disorders, psoriasis, urticaria, 
eczema, infections of the skin, or pruritus. Sexual im-
pact was strongly associated with depression, anxiety, 
and suicidal ideation. It was generally more frequent 
in younger patients and was positively correlated with 
clinical severity and itch. It is important to address the 
issue of sexual well-being in the evaluation of patients 
with skin conditions, since it is often linked to anxiety, 
depression, and even suicidal ideation. 
Key words: skin; quality of life; sexual impairment; hidradenitis 
suppurativa; Dermatology Life Quality Index.
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Sexual life is an important component of health-related quality of life. Skin conditions may have a strong 
impact on this component, since they involve appearance, 
and thus affect social life and personal relationships. Se-
veral studies have investigated the impact of venereologi-
cal and dermatological diseases with genital localization 
on sexual life (1–3). However, regardless of the localiza-
tion of the affected body area, the involvement of skin 
in a disease may have consequences on intimacy (4, 5). 
In clinical practice, it may be challenging for both 
the patient and the physician to discuss sensitive issues 
directly, so the impact of a disease on sexual life is 
rarely assessed. Self-assessment using questionnaires 
may provide a viable alternative. Several specific ques-
tionnaires aimed at measuring sexual quality of life are 
available (6), and even a single question from a generic 
or disease-specific quality of life instrument may yield 
some important information. 
A relevant issue in the interpretation of studies on 
quality of life in general, and of the impact of skin di-
seases on sexual life, derives from the vast cultural and 
methodological variations between countries and study 
design, as well from the use of different questionnaires. 
Therefore, we planned a multicentre European ini-
tiative to provide insight on the impact of skin diseases 
on quality of life and psychological wellbeing, using 
a single study design with standardized procedures 
and common research tools (7). The aim of the present 
study was to investigate the perceived impact of several 
dermatological conditions on patients’ sexual life, using 
item 9 of the Dermatology Life Quality Index (DLQI) 
(8), across clinical and demographic variables in 13 
European countries. 
METHODS
Data presented in this report come from a large, cross-sectional 
study on the psychological burden of skin diseases conducted in 
13 European countries. The materials and methods were descri-
bed in detail in the main paper (7). In brief, complete data were 
collected on 3,635 consecutive, dermatological out-patients, and 
1,359 healthy controls. The present report, being focused on the 
impact of skin diseases on the patients’ sexual life, is based on data 
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collected from the dermatology-specific instrument DLQI, and 
therefore considers only the out-patients’ sample. The inclusion 
criteria were: age 18 years and over; able to read and write the 
local language; and not having any severe psychiatric diseases. 
Each patient was examined by a dermatologist who recorded the 
diagnosis and the presence of other physical conditions. Patients 
completed a questionnaire including socio-demographic variables. 
The Hospital Anxiety and Depression Scale (HADS) (9, 10) was 
used to evaluate the presence and severity of depression and/or 
anxiety in patients. It includes 7 items assessing anxiety and 7 
assessing depression, each with 4 possible answers. For each di-
mension of anxiety and depression a score from 0 to 7 is considered 
a normal case, from 8 to 10 a borderline case, and from 11 to 21 
a case in need of further examination or treatment. The clinical 
severity of the skin condition was evaluated by the physician as 
either “mild”, “moderate”, or “severe”. 
The sexual impact due to the skin condition was evaluated using 
item 9 of the DLQI (8). The question is: “Over the last week, how 
much has your skin caused any sexual difficulties?”, with the 
possible answers “very much” (3), “a lot” (2), “a little” (1), “not 
at all/not relevant” (0). 
The frequency of each answer for the different dermatological 
conditions was calculated, and the association of sexual impair-
ment with different variables was studied, including socio-de-
mographic (sex, age, “living in the country of origin”, education, 
marital status, geographical region) and clinical information 
(clinical severity of the skin condition, body site, and itch). The 
answers to item 9 were grouped in order to have a dichotomous 
variable “yes/no” (answers “very much” [3], “a lot” [2], and “a 
little” [1] vs. “not at all/not relevant” [0]). Countries were grouped 
into Northern Europe (Denmark, Norway), Western Europe (Bel-
gium, France, Germany, The Netherlands, UK), Eastern Europe 
(Hungary, Poland, Russia, Turkey), and Southern Europe (Italy, 
Spain). Frequencies were compared using the χ2 test. 
Logistic regression models were tested for some diseases se-
lected on the basis of the number of patients (eczema, psoriasis, 
acne), and/or the strong prevalence of sexual problems (blistering 
disorders). The diagnosis “eczema” included atopic dermatitis, 
eczema, and hand eczema. The dichotomous variable DLQI_9 
(presence/absence of sexual difficulties) was introduced in each 
model as the dependent variable. The independent variables were 
age, sex, clinical severity, European region, flare on scalp, flare 
on hands, itch, anxiety, and depression. 
RESULTS
Data were complete for both question 9 of the DLQI and 
diagnosis in 3,485 patients. The 114 patients with a diag-
nosis, but with no answer to question 9 of the DLQI were 
older than patients who answered the question (mean age 
56.8 vs. 46.8 years among patients who did not answer 
and who answered question 9, respectively, p < 0.001), 
and included more women (65.8% vs. 56.1%, p = 0.027). 
Overall, 11.7% of patients reported sexual difficulties “a 
little”, 5.5% “a lot”, and 5.9% “very much”. Spearman’s 
correlation between item 9 and the DLQI total score was 
0.558. We also verified the correlation between item 9 
and the sum of all the other DLQI items: the Spearman’s 
correlation coefficient remained in the “moderate” range, 
although at a lower level (i.e. 0.501).
As shown in Table I, there was no significant diffe-
rence between men and women, while sexual impairment 
was reported more frequently by younger patients. No 
differences were observed in patients with different 
marital status and different origin (i.e. either coming 
from a foreign country or not). In Southern countries 
the prevalence of sexual difficulties was significantly 
higher compared with the other geographical areas. In 
patients with a clinically severe condition, the prevalence 
of sexual problems was 3 times more frequent among 
patients answering “a lot”, and 4 times more frequent for 
those answering “very much” compared with patients 
with a clinically mild condition. Also, flares on the scalp 
and on the hands, as well as itch, were significantly as-
sociated with sexual problems. 
Sexual difficulties were strongly associated with both 
depression and anxiety (Table II). For example, among 
depressed patients, 24.3% reported sexual difficulties “a 
lot” or “very much”, compared with 7.3% of non-depres-
sed patients. For anxiety the percentages were, respec-
tively, 20.7% and 5.9%. Among patients who reported 
Table I. Prevalence of sexual difficulties in the study population 
according to demographic and clinical variables
Variable na
Sexual difficulties (DLQI_9)
p-value
Not at all/
not relevant 
%
A little 
%
A lot 
%
Very 
much 
%
Overall 3,485 76.9 11.7 5.5 5.9
Sex 
  Male 1,524 75.1 13.0 5.6 6.2
  Female 1,950 78.3 10.7 5.3 5.6 ns
Age
  18–39 years 1,310 73.3 13.1 6.6 7.0
  40–59 years 1,171 73.7 13.3 6.1 6.8
  ≥ 60 years  942 85.8 7.3 3.3 3.6 < 0.001
Origin
  Home 3,170 77.1 11.8 5.5 5.6
  Foreign  245 73.1 11.8 6.5 8.6 ns
Education
  Primary 1,425 80.2 9.3 4.5 6.0
  Secondary 1,031 73.4 13.5 6.8 6.3
  University  996 75.9 13.4 5.5 5.2 0.001
Marital status
  Single 846 75.3 13.2 5.6 5.9
  Married 1,914 77.8 11.1 5.3 5.7
  Divorced  265 73.6 11.3 7.9 7.2
  Widow/widower  196 83.2 8.7 2.6 5.6 ns
Region of Europe
  Northern  724 76.0 12.7 5.5 5.8
  Western 1,046 83.3 9.0 3.3 4.4
  Eastern  967 77.4 9.9 6.2 6.5
  Southern  748 68.4 16.8 7.4 7.4 < 0.001
Severity
  Mild 1,183 84.7 9.5 3.0 2.9
  Moderate 1,408 72.3 14.4 6.7 6.5
  Severe  521 65.3 12.9 8.8 13.1 < 0.001
Flare on face
  Yes 1,262 78.6 11.3 4.6 5.5
  No 2,150 75.3 12.3 6.0 6.3 ns
Flare on scalp
  Yes  908 72.4 13.7 5.7 8.3
  No 2,509 78.1 11.3 5.5 5.2 0.001
Flare on hands
  Yes 1,037 70.0 13.7 7.5 8.8
  No 2,379 79.4 11.1 4.7 4.8 < 0.001
Itch
  Yes 1,863 68.8 15.4 7.6 8.2
  No 1,568 86.2 7.7 2.8 3.3 < 0.001
aTotals may vary because of missing figures.
DLQI: Dermatology Life Quality Index.
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thoughts of suicide due to their skin condition 30.5% 
reported sexual difficulties “very much”, compared with 
9.9% of patients who did not have thoughts of suicide.
As shown in Fig. 1, which summarizes the prevalence 
of the answers “a lot/very much/a little” to question 9 
of the DLQI, the impairment was particularly high in 
patients with hidradenitis suppurativa (66.7%). Other 
diagnoses with a prevalence greater than 1/3 were pru-
rigo (41.7%), blistering disorders (34.9%), and psoriasis 
(34.8%); these were followed by urticaria and eczema 
(both at 29.0%), infections of the skin (27.7%), and 
pruritus (27.6%). The lowest prevalence was reported by 
patients with non-melanoma skin cancer (6.1%), naevi 
(6.4%), benign skin tumours (10.8%), and melanoma 
(12.8%). 
When studying the role of sex in the different skin 
conditions, it was observed that in patients with acne the 
impact on sexual life was higher in men than in women 
(23.5% of positive answers to item 9 and 12.2%, respecti-
vely, p < 0.05). For all the other conditions, the difference 
between men and women was not significant. The higher 
impact on sexual life observed overall in younger patients 
was significant only in patients with psoriasis (38.2% of 
positive answers in patients up to 60 years old, and 21.6% 
in patients older than 60 years, p < 0.05), with blistering 
disorders (47.1% and 23.1%, respectively, p < 0.05), and 
with eczema (31.5% and 16.0%, respectively, p < 0.05).
In patients with eczema (Table III), sexual difficul-
ties were significantly associated with young age, high 
severity, itch, anxiety and depression. In patients with 
psoriasis, sexual impairment was associated with young 
age, itch, anxiety, and depression. In patients with acne, 
sexual impact was associated with sex (higher impact in 
men), flare on hands, and itch. As for blistering diseases, 
because of the small number of patients, significance was 
reached only for clinical severity. However, there was a 
strong association between sexual impact and young age. 
It was not possible to test the model for hidradenitis 
suppurativa, due to the low number of patients, however a 
strong association, although not significant, was observed 
between sexual impact and young age, clinical severity, 
itch, and anxiety. 
DISCUSSION
In this study, the impact of dermatological conditions 
on sexual life was investigated with simple standardized 
procedures in a large population of dermatological pa-
tients recruited in different European areas. The impact 
was particularly high in patients with hidradenitis sup-
purativa, prurigo, blistering disorders, psoriasis, urticaria, 
eczema, infections of the skin and pruritus. The important 
impact of hidradenitis suppurativa, which is a chronic, 
debilitating suppurative skin disease (11), on quality of 
life and on a wide spectrum of psychophysical aspects 
(including fatigue, depression, stigmatization level, and 
Table II. Frequency of sexual difficulties in the study population 
according to mood disorders
n
Sexual difficulties (DLQI_9)
Not at 
all 
%
A little 
%
A lot 
%
Very 
much 
%
No depression 2,618 82.1 10.6   3.8   3.5
Marginal or clinical depression    824 60.3 15.4 10.7 13.6*
No anxiety 2,168 84.3   9.8   3.0   2.9
Marginal or clinical anxiety 1,270 64.2 15.0   9.8 10.9*
No thoughts of suicide 3,226 78.6 11.5   4.8   5.1
Thoughts of suicide    233 54.1 15.5 12.9 17.6*
*p < 0.001.
DLQI: Dermatology Life Quality Index.
Fig. 1. Prevalence of positive answers to question 9 of the Dermatology Life Quality Index (DLQI) (“Over the last week, how much has your 
skin caused any sexual difficulties?”) in different skin conditions. NMSC: non-melanoma skin cancer.
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overall activity) has been documented (12, 13); however, 
to our knowledge, sexual impact had not been specifically 
evaluated. 
Decreased sexual functioning has been reported in 
patients with psoriasis (4, 14). In both studies, sexual 
impact was evaluated using single questions. In the first 
study, 40.8% of patients were sexually affected based 
on the question “Do you believe that since the onset 
of psoriasis your sexual activity has declined?”. In the 
other study, sexual life was impaired in 35–71% of pa-
tients with psoriasis, depending on the different aspects 
covered by questions from different questionnaires. 
Another study (15) showed that psoriasis patients had 
more problems with orgasm than with desire, and stated 
that problems with orgasm might be due to disturbed 
self-esteem or emotional problems rather than severity 
or localization of the disease. One study (16) showed 
that psoriasis had a detrimental effect on quality of life 
and sexual health, in particular when the lesions were 
localized on the genital area, and in women more than 
in men. In the present study, sexual impact in patients 
with psoriasis was significantly associated with young 
age, itch, anxiety, and depression. The relevant role of 
itch was previously highlighted by Yosipovitch et al. (17) 
who reported that, as result of pruritus, sexual desire of 
35% of study participants was decreased or non-existent.
The issue of sexual life was also examined from a qua-
litative point of view in patients with acne, psoriasis, and 
atopic eczema (18). These conditions had adverse effects 
on participants’ self-perceived sexual attractiveness and 
self-confidence, and in particular psoria-
sis and eczema also had marked effects 
on sexual well-being and on capacity 
for intimacy. 
Several studies have addressed the 
sexual life of patients with atopic derma-
titis. Misery et al. (5) showed that 57.5% 
of patients with atopic dermatitis noted 
decreased sexual desire, and 36.7% of 
their partners reported that the appea-
rance of eczema had an impact on their 
sexual life. A German study showed that 
the exchange of tenderness in patients 
with atopic dermatitis and psoriasis was 
significantly reduced (19). Sexual life 
was studied in detail in Turkish patients 
with vitiligo and chronic urticaria (20), 
who reported experiencing significantly 
more difficulties in sexual arousal and in 
reaching orgasm than did controls. In a 
large French population aged from 15 
to 24 years, the presence of acne was 
associated with less frequent sexual 
intercourse compared with the control 
group (21). Since adolescents are the 
main group with acne (22), and our po-
pulation did not include patients under 18 years of age, 
the impact of acne in total is probably even greater than 
what we observed. Sexual life was more impaired in 
men with acne, probably because it is easier for women 
to hide the lesions using make-up. 
A possible explanation for all these findings is not 
only that the condition may affect the genital area, and 
thus result in pain or discomfort, but also that the skin 
has an erotogenic function, and skin lesions can make 
physical contact difficult. Although this issue may be 
very burdensome for the individual, this problem is rarely 
addressed during routine dermatological consultations. 
In the study by Niemeier et al. (19), 93% of patients with 
psoriasis and 96% of the patients with atopic dermatitis 
indicated that their attending physician had never addres-
sed that problem. 
In this study, we observed that sexual impact was 
strongly associated with itch, depression, anxiety, and 
even suicidal ideation. The cross-sectional nature of 
the study does not allow the sorting out of the complex 
interrelationship between the onset of disease, itch, the 
presence of anxiety and/or depression, and the sexual 
problems. Therefore, while it is not possible to draw 
any conclusion on the direction of the association, it is 
important to be aware that sexual impairment is often 
a marker for depression or anxiety, and even suicidal 
ideation and vice versa. Also, the correlation between 
item 9 of the DLQI and the DLQI total score was high, 
indicating that an impairment in sexual life often cor-
responds with a general impairment in quality of life. 
Table III. Logistic regression models for eczema, psoriasis, acne, and blistering 
disorders, with sexual impact as the dependent variables. The odds ratios (OR) were 
also adjusted for region
Variable
Eczema 
(n = 448) 
OR (95% CI)
Psoriasis 
(n = 537) 
OR (95% CI)
Acne 
(n = 202) 
OR (95% CI)
Blistering disorders 
(n = 53) 
OR (95% CI)
Age
  ≥ 60 years Ref. Ref. Ref. Ref.
  18–39 years 2.23 (1.09–4.58) 2.27 (1.30–3.97) 4.93 (0.42–57.27) 4.80 (0.39–58.58)
  40–59 years 3.25 (1.57–6.72) 2.14 (1.24–3.69) – 3.06 (0.61–15.40)
Sex
  Women Ref. Ref. Ref. Ref.
  Men 1.30 (0.82–2.06) 1.25 (0.84–1.85) 2.42 (1.00–5.89) 0.90 (0.19–4.13)
Severity
  Mild Ref. Ref. Ref. Ref.
  Moderate 2.16 (1.29–3.61) 1.35 (0.84–2.18) 1.88 (0.67–5.29) 4.79 (0.77–29.65)
  Severe 1.84 (0.90–3.75) 1.36 (0.77–2.41) 2.60 (0.74–9.11) 10.12 (1.02–100.57)
Flare scalp
  No Ref. Ref. Ref. Ref.
  Yes 1.06 (0.62–1.82) 1.05 (0.71–1.56) 0.97 (0.26–3.61) 2.24 (0.35–14.45)
Flare hands
  No Ref. Ref. Ref. Ref.
  Yes 1.18 (0.73–1.92) 1.09 (0.72–1.64) 1.16 (0.21–6.40) 1.61 (0.29–8.97)
Itch
  No Ref. Ref. Ref. Ref.
  Yes 2.66 (1.27–5.57) 1.86 (1.14–3.03) 3.81 (1.41–10.28) 0.30 (0.04–2.02)
Anxiety
  No Ref. Ref. Ref. Ref.
  Yes 1.71 (1.02–2.86) 1.98 (1.25–3.12) 1.32 (0.50–3.51) 1.88 (0.33–10.79)
Depression
  No Ref. Ref. Ref. Ref.
  Yes 1.99 (1.15–3.45) 2.05 1.27–3.30 1.03 (0.32–3.34) 0.66 (0.10–4.42)
Bold figures indicate significant ORs. CI: confidence interval.
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An important issue is that sexual problems particularly 
affect young patients. It was observed (23) that, for 
example, the impact of psoriasis on quality of life was 
particularly noticeable in younger patients, while the 
symptomatic component, due to comorbidities, was more 
impaired in older patients. Sexual life is an important 
component of well-being, in particular in young people, 
and it is thus particularly impaired when a skin condi-
tion is present. 
A limitation of this study is the use of a single simple 
question, which is not specifically validated to assess 
the sexual impact of dermatological conditions, and 
therefore does not allow one to evaluate in detail which 
aspects of sexual life are impaired. However, the aim 
of this study was to highlight the problem in general, 
and further studies are necessary to elucidate the single 
specific factors (such as, for example, shame or anger, 
or body site of the lesions, such as genital localization of 
rash, pruritus, etc.) that may be associated with a greater 
impairment of the patients’ sexual life in the different 
skin conditions. Furthermore, other complex symptoms, 
such as pain and itch, may be adequately screened for 
by simple questions, identifying and quantifying the 
problems before detailed analysis.
Another limitation is that patients were not asked if 
they have or they would like to have an active sexual 
life. The possible answers to question 9 of the DLQI 
include both “not at all” and also “not relevant”. Both of 
these options score 0. It would have been of interest to 
have analysed the data set excluding those patients who 
answered “not relevant”, but the data collection process 
did not distinguish between these 2 groups.
The results of the study reinforce the idea that it is 
important to take into account specific psychosocial pro-
blems, such as sexual life, when assessing severity and 
treatment efficacy in dermatological conditions. Having 
this screening, sexual impairment question “hidden” in 
the DLQI may make it easier to bring up the subject 
and address these issues in the clinic. Clinicians should 
be especially aware of the ability of several dermato-
logical conditions to profoundly affect patients’ sexual 
well-being, which in turn is often linked to a range of 
psychological comorbidities.
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